Chatelut É - Search Results

1

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.

Maillard M, Chevreau C, Le Louedec F, Cassou M, Delmas C, Gourdain L, Blay JY, Cupissol D, Bompas E, Italiano A, Isambert N, Delcambre-Lair C, Penel N, Bertucci F, Guillemet C, Plenecassagnes J, Foulon S, Chatelut É, Le Cesne A, Thomas F. Maillard M, et al. Among authors: chatelut e. Cancers (Basel). 2020 Dec 4;12(12):3647. doi: 10.3390/cancers12123647. Cancers (Basel). 2020. PMID: 33291741 Free PMC article.

2

[Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].

Chatelut E, Canal P, De Forni M, Chevreau C, Houin G, Bugat R. Chatelut E, et al. Bull Cancer. 1989;76(8):893-6. Bull Cancer. 1989. PMID: 2620120 French. No abstract available.

3

A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.

Chatelut E, Chevreau C, Brunner V, Martinez M, Houin G, Bugat R, Canal P. Chatelut E, et al. Cancer Chemother Pharmacol. 1995;35(5):391-6. doi: 10.1007/s002800050252. Cancer Chemother Pharmacol. 1995. PMID: 7850920 Clinical Trial.

4

How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.

Bénézet S, Guimbaud R, Chatelut E, Chevreau C, Bugat R, Canal P. Bénézet S, et al. Among authors: chatelut e. Ann Oncol. 1997 Jun;8(6):607-9. doi: 10.1023/a:1008259009500. Ann Oncol. 1997. PMID: 9261532 Free article.

5

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

Chatelut E, Pivot X, Otto J, Chevreau C, Thyss A, Renée N, Milano G, Canal P. Chatelut E, et al. Eur J Cancer. 2000 Jan;36(2):264-9. doi: 10.1016/s0959-8049(99)00266-x. Eur J Cancer. 2000. PMID: 10741287

6

Dexamethasone as a probe for docetaxel clearance.

Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Azéma J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roché H. Puisset F, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 2004 Sep;54(3):265-72. doi: 10.1007/s00280-004-0823-0. Epub 2004 May 5. Cancer Chemother Pharmacol. 2004. PMID: 15133628 Clinical Trial.

7

Serum cystatin C is a better marker of topotecan clearance than serum creatinine.

Hoppe A, Séronie-Vivien S, Thomas F, Delord JP, Malard L, Canal P, Chatelut E. Hoppe A, et al. Among authors: chatelut e. Clin Cancer Res. 2005 Apr 15;11(8):3038-44. doi: 10.1158/1078-0432.CCR-04-2086. Clin Cancer Res. 2005. PMID: 15837759 Clinical Trial.

8

Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients.

Séronie-Vivien S, Toullec S, Malard L, Thomas F, Durrand V, Chatelut E. Séronie-Vivien S, et al. Among authors: chatelut e. Med Oncol. 2006;23(1):63-73. doi: 10.1385/MO:23:1:63. Med Oncol. 2006. PMID: 16645231

9

Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.

Delbaldo C, Chatelut E, Ré M, Deroussent A, Séronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G. Delbaldo C, et al. Among authors: chatelut e. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6073-8. doi: 10.1158/1078-0432.CCR-05-2596. Clin Cancer Res. 2006. PMID: 17062683

10

[Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys].

Thomas F, Séronie-Vivien S, Malard L, Chatelut E. Thomas F, et al. Among authors: chatelut e. Therapie. 2007 Mar-Apr;62(2):121-7. doi: 10.2515/therapie:2007019. Epub 2007 Jun 21. Therapie. 2007. PMID: 17582313 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page